Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Clinical Pharmacology Market: By Phase, By Study Design, By Therapeutic Area and Region Forecast 2019-2030
Clinical Pharmacology Market size was valued at US$ 48,376.3 million in 2023 and is poised to grow at a significant CAGR of 8.5% from 2024-2030. Clinical pharmacology is concerned with all aspects of the interaction between medications and humans. It is the NHS's sole medical specialty devoted to the safe, efficient, and cost-effective use of medications. It is a varied field that both preserves and improves excellent practices in healthcare. The Phase III segment is anticipated to grow at a significant CAGR over the forecast years, owing to the segment being classified into four phases: Phase I, Phase II, Phase III, and Phase IV. The relatively large patient population and the utilization of advanced research services to investigate medication efficacy have led to the rise of the Phase III segment. These complicated clinical trials need both clinical resources and powerful technologies in order to recruit patients, establish trial sites promptly, and provide cost-effective and high-quality study management efficiently. The bulk of global pharmaceutical, biopharmaceutical, and medical device firms outsource Phase III clinical trial services to clinical trial service providers.
Moreover, the competitive players are focusing on collaboration and acquisition to maintain growth in the forecasting market. For Instance, In September 2021, Syneos Health entered a strategic collaboration with Ride Health to offer non-emergency medical transportation (NEMT) for clinical trial participants. Factors such as increased R&D investment, rising need for R&D outsourcing, and an increase in the number of clinical trials for various illnesses globally are propelling the global market forward.
Study Period
2024-2030Base Year
2023CAGR
8.5%Largest Market
Asia PacificFastest Growing Market
North America
As the need for breakthrough pharmaceuticals and enhanced medical technology rises, the demand for efficient, fast-paced, and trustworthy clinical trial programs will increase. Furthermore, the medicine development process is extremely risky for biotechnology and pharmaceutical companies, with substantially lower approval rates and associated high costs. As a result, it was concluded that outsourcing the clinical trials program to numerous contract research organizations (CROs) would save the pharmaceutical business significant time and money. Specific contract research organizations (CRO) regional penetration has also been recorded. Thus, the spike in demand for clinical trial outsourcing is fueling the clinical trials market development throughout the forecast period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 48,376.3 million |
Market CAGR |
8.5% |
By Phase |
|
By Study Design |
|
By Therapeutic Area |
|
Download Free Sample Report
The global clinical pharmacology market size was valued at US$ 48.3 billion in 2023 and is projected to grow at a CAGR of 8.5% from 2024 to 2030.
The clinical pharmacology market key players are: IQVIA (US) LabCorp (US) Charles River Laboratories (US) WuXi AppTec (China) Syneos Health (US) Parexel International (US) PPD (US) ICON Plc (US) Medpace Holdings (US) SGS (Switzerland)
The clinical pharmacology market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Clinical Pharmacology Market Introduction |
2.1. Global Clinical Pharmacology Market Taxonomy |
2.2. Global Clinical Pharmacology Market Definitions |
2.2.1. By Phase |
2.2.2. By Study Design |
2.2.3. By Therapeutic Area |
2.2.4. By Region |
3. Global Clinical Pharmacology Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Clinical Pharmacology Market Dynamic Factors - Impact Analysis |
3.6. Global Clinical Pharmacology Market Competition Landscape |
4. Global Clinical Pharmacology Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 |
4.1. Market Analysis,2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Clinical Pharmacology Market, By Phase, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1. Phase I |
5.1.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Phase II |
5.2.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Phase III |
5.3.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Phase IV |
5.4.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Clinical Pharmacology Market Forecast, By Study Design, 2019 - 2030 and Forecast, 2021 2027 (Revenue, USD Mn) |
6.1. Interventional Study |
6.1.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Observational Study |
6.2.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Expanded Access Study |
6.3.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Clinical Pharmacology Market, By Therapeutic Area, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1. Autoimmune Disease |
7.1.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Oncology |
7.2.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Cardiology |
7.3.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Infectious Disease |
7.4.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Dermatology |
7.5.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Ophthalmology |
7.6.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.6.3. Market Opportunity Analysis |
7.7. Others |
7.7.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.7.3. Market Opportunity Analysis |
8. Global Clinical Pharmacology Market Forecast, By Region, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Clinical Pharmacology Market - Opportunity Analysis Index, By Phase, By Study Design, Therapeutic Area, and Region, 2024 - 2030 |
9. North America Clinical Pharmacology MarketAnalysis,2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1. By Phase Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Phase I |
9.1.2. Phase II |
9.1.3. Phase III |
9.1.4. Phase IV |
9.2. By Study Design Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.2.1. Interventional Study |
9.2.2. Observational Study |
9.2.3. Expanded Access Study |
9.3. By Therapeutic Area Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Autoimmune Disease |
9.3.2. Oncology |
9.3.3. Cardiology |
9.3.4. Infectious Disease |
9.3.5. Dermatology |
9.3.6. Ophthalmology |
9.3.7. Others |
9.4. Country Analysis 2019 - 2030 and Forecast 2024 - 2030by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. USA |
9.4.2. Canada |
9.5. North America Clinical Pharmacology Market - Opportunity Analysis Index, By Phase, By Study Design, Therapeutic Area, and Country, 2024 - 2030 |
9.6. North America Clinical Pharmacology Market Dynamics Trends |
10. Europe Clinical Pharmacology Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
10.1. By Phase Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Phase I |
10.1.2. Phase II |
10.1.3. Phase III |
10.1.4. Phase IV |
10.2. By Study Design Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Interventional Study |
10.2.2. Observational Study |
10.2.3. Expanded Access Study |
10.3. By Therapeutic Area Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Autoimmune Disease |
10.3.2. Oncology |
10.3.3. Cardiology |
10.3.4. Infectious Disease |
10.3.5. Dermatology |
10.3.6. Ophthalmology |
10.3.7. Others |
10.4. Country Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Rest of Europe |
10.5. Europe Clinical Pharmacology Market - Opportunity Analysis Index, By Phase, By Study Design, Therapeutic Area, and Country, 2024 - 2030 |
10.6. Europe Clinical Pharmacology Market Dynamics Trends |
11. Asia-Pacific Clinical Pharmacology Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
11.1. By Phase Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Phase I |
11.1.2. Phase II |
11.1.3. Phase III |
11.1.4. Phase IV |
11.2. By Study Design Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Interventional Study |
11.2.2. Observational Study |
11.2.3. Expanded Access Study |
11.3. By Therapeutic Area Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Autoimmune Disease |
11.3.2. Oncology |
11.3.3. Cardiology |
11.3.4. Infectious Disease |
11.3.5. Dermatology |
11.3.6. Ophthalmology |
11.3.7. Others |
11.4. Country Analysis2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Japan |
11.4.2. China |
11.4.3. India |
11.4.4. ASEAN |
11.4.5. Australia & New Zealand |
11.4.6. Rest of Asia-Pacific |
11.5. Asia-Pacific Clinical Pharmacology Market - Opportunity Analysis Index, By Phase, By Study Design, Therapeutic Area, and Country, 2024 - 2030 |
11.6. Asia-Pacific Clinical Pharmacology Market Dynamics Trends |
12. Latin America Clinical Pharmacology Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
12.1. By Phase Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Phase I |
12.1.2. Phase II |
12.1.3. Phase III |
12.1.4. Phase IV |
12.2. By Study Design Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Interventional Study |
12.2.2. Observational Study |
12.2.3. Expanded Access Study |
12.3. By Therapeutic Area Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Autoimmune Disease |
12.3.2. Oncology |
12.3.3. Cardiology |
12.3.4. Infectious Disease |
12.3.5. Dermatology |
12.3.6. Ophthalmology |
12.3.7. Others |
12.4. Country Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Argentina |
12.4.4. Rest of Latin America |
12.5. Latin America Clinical Pharmacology Market - Opportunity Analysis Index, By Phase, By Study Design, Therapeutic Area, and Country, 2024 - 2030 |
12.6. Latin America Clinical Pharmacology Market Dynamics Trends |
13. Middle East and Africa Clinical Pharmacology Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
13.1. By Phase Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Phase I |
13.1.2. Phase II |
13.1.3. Phase III |
13.1.4. Phase IV |
13.2. By Study Design Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Interventional Study |
13.2.2. Observational Study |
13.2.3. Expanded Access Study |
13.3. By Therapeutic Area Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Autoimmune Disease |
13.3.2. Oncology |
13.3.3. Cardiology |
13.3.4. Infectious Disease |
13.3.5. Dermatology |
13.3.6. Ophthalmology |
13.3.7. Others |
13.4. Country Analysis 2019 - 2030 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Gulf Cooperation Council (GCC) Countries |
13.4.2. Israel |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Clinical Pharmacology Market - Opportunity Analysis Index, By Phase, By Study Design, Therapeutic Area, and Country, 2024 - 2030 |
13.6. MEA Clinical Pharmacology Market Dynamics Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, By Study Design & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. IQVIA (US) |
14.2.2. LabCorp (US) |
14.2.3. Charles River Laboratories (US) |
14.2.4. WuXi AppTec (China) |
14.2.5. Syneos Health (US) |
14.2.6. Parexel International (US) |
14.2.7. PPD (US) |
14.2.8. ICON Plc (US), |
14.2.9. Medpace Holdings (US) |
14.2.10. SGS (Switzerland) |
15. Research Methodology |
16. Key Assumptions and Acronyms |
Key Market Players